© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
LivaNova PLC (LIVN) stock declined over -0.05%, trading at $65.15 on NASDAQ, down from the previous close of $65.18. The stock opened at $65.19, fluctuating between $64.24 and $65.61 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 22, 2026 | 64.80 | 65.69 | 64.55 | 65.18 | 459.76K |
| Apr 21, 2026 | 65.89 | 67.30 | 64.22 | 64.53 | 1.02M |
| Apr 20, 2026 | 67.12 | 68.00 | 65.41 | 65.81 | 722.69K |
| Apr 17, 2026 | 65.98 | 68.04 | 65.98 | 67.12 | 768.29K |
| Apr 16, 2026 | 64.88 | 65.31 | 64.20 | 65.01 | 556.37K |
| Apr 14, 2026 | 64.66 | 65.61 | 64.59 | 64.99 | 399.23K |
| Apr 13, 2026 | 62.26 | 64.70 | 62.03 | 64.58 | 636.75K |
| Apr 10, 2026 | 63.30 | 64.17 | 61.85 | 62.78 | 620.72K |
| Apr 09, 2026 | 63.86 | 64.30 | 63.27 | 63.37 | 641.58K |
| Apr 08, 2026 | 66.72 | 66.72 | 63.87 | 64.66 | 1.02M |
| Apr 07, 2026 | 63.35 | 64.19 | 62.15 | 63.54 | 610.97K |
| Apr 06, 2026 | 63.21 | 64.17 | 63.17 | 63.50 | 588.06K |
| Apr 02, 2026 | 62.53 | 65.09 | 62.41 | 63.79 | 678.91K |
| Apr 01, 2026 | 63.83 | 65.21 | 63.69 | 64.63 | 637.97K |
| Mar 31, 2026 | 61.86 | 64.01 | 60.35 | 63.56 | 1.13M |
| Mar 30, 2026 | 62.04 | 62.65 | 61.13 | 61.27 | 621.3K |
| Mar 27, 2026 | 62.89 | 63.55 | 60.63 | 61.85 | 759.28K |
| Mar 25, 2026 | 63.24 | 63.65 | 61.62 | 63.30 | 514.27K |
| Mar 24, 2026 | 62.49 | 63.68 | 61.98 | 62.40 | 647.87K |
| Mar 23, 2026 | 63.58 | 64.06 | 62.95 | 63.24 | 671.82K |
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
| Employees | 2900 |
| Beta | 0.97 |
| Sales or Revenue | $1.15B |
| 5Y Sales Change% | -0.062% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |